Publication

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…

CertaraJuly 29, 2026

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

Publication

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…

CertaraOctober 31, 2025

Conference

ICAComP 2025

CertaraOctober 8, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Poster

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

CertaraNovember 22, 2024

Blog

Local therapies for the global COVID-19 pandemic

Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as…

CertaraMay 29, 2020

Blog

Applying decision analysis to drug development for COVID-19 & future pandemics

This blog discusses how decision analysis approaches can help drug developers to better decisions under…

CertaraApril 30, 2020

Publication

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

CertaraJanuary 17, 2020

Infectious Disease

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

ICAComP 2025

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

Local therapies for the global COVID-19 pandemic

Applying decision analysis to drug development for COVID-19 & future pandemics

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Newsletter sign up

Quick links

Solutions

Contact